Literature DB >> 1969451

Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones.

D T Umetsu1, L Esserman, T A Donlon, R H DeKruyff, R Levy.   

Abstract

We examined stimuli which are required for the induction of in vitro proliferation of follicular lymphoma cells, a low grade non-Hodgkin's B cell lymphoma characterized by a specific chromosomal translocation, t(14;18)(q32;q21), and by in vivo growth of the lymphoma cells in germinal center-like follicles infiltrated with CD4+ T cells. The purified follicular lymphoma cells, which are morphologically uniform, small, and dense, did not respond to stimulation with soluble lymphokines in the absence of T cells. Vigorous in vitro proliferation of follicular lymphoma cells was induced, however, when the follicular lymphoma cells were cultured with a CD4+ T cell clone which recognized alloantigens expressed by the lymphoma cells. This response required B-T cell contact, and was inhibited by anti-class II but not by anti-class I MHC mAb, indicating that these neoplastic B cells behaved as normal B cells and responded to normal activation and differentiation signals from T cells. After the cognate B lymphoma-T cell interaction occurred in culture, addition of IL-2 or IL-4 enhanced the proliferation of the tumor cells. These results, with a monoclonal and homogeneous population of B cells, affirm the idea that cognate interaction between B cells and Th cells is required for the effective activation of resting B cells. Moreover, these results suggest that a critical host-tumor interaction occurs in vivo, and that the polyclonal CD4+ T cells that infiltrate follicular lymphomas play a role in sustaining rather than inhibiting tumor growth in vivo. If so, therapies directed not only against the neoplastic cell but also against specific T cells and their cognate interactions with tumor cells may have a rationale.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969451

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  Superantigens related to B cell hyperplasia.

Authors:  N M Ponzio; V K Tsiagbe; G J Thorbecke
Journal:  Springer Semin Immunopathol       Date:  1996

Review 2.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

3.  Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment.

Authors:  W Richard Burack; Janice M Spence; John P Spence; Stephen A Spence; Philip J Rock; Gautam N Shenoy; Leonard D Shultz; Richard B Bankert; Steven H Bernstein
Journal:  Blood Adv       Date:  2017-07-07

4.  CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.

Authors:  A Carbone; A Gloghini; H J Gruss; A Pinto
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

5.  Cytofluorimetric analysis of mitogen-activated peripheral blood lymphocytes of non-leukemic lymphoma patients reveals an abnormal disease-related expression pattern of activation antigens.

Authors:  H Mangge; F Beaufort; W Kaulfersch; E Rossipal; K Schauenstein
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 6.  Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.

Authors:  John G Gribben; Nathan Fowler; Franck Morschhauser
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

7.  IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma.

Authors:  Katherine R Calvo; Bhavana Dabir; Alexandra Kovach; Christopher Devor; Russell Bandle; Amelia Bond; Joanna H Shih; Elaine S Jaffe
Journal:  Blood       Date:  2008-08-05       Impact factor: 22.113

8.  Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.

Authors:  Roch Houot; Matthew J Goldstein; Holbrook E Kohrt; June H Myklebust; Ash A Alizadeh; Jack T Lin; Jonathan M Irish; James A Torchia; Arne Kolstad; Lieping Chen; Ronald Levy
Journal:  Blood       Date:  2009-07-29       Impact factor: 22.113

9.  Interleukin 3 is a growth factor for human follicular B cell lymphoma.

Authors:  C Clayberger; S Luna-Fineman; J E Lee; A Pillai; M Campbell; R Levy; A M Krensky
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

Review 10.  The tumour microenvironment in B cell lymphomas.

Authors:  David W Scott; Randy D Gascoyne
Journal:  Nat Rev Cancer       Date:  2014-07-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.